Medical news and careers, clearly connected
CareZelo
English
Menu

Mises à jour en santé publique

Échéance dans 11 joursSanté publiqueCanada

Sandoz reports supply shortage of sufentanil injection through early November

Sandoz Canada reports its sufentanil citrate injection 50 mcg (DIN 02244147), for epidural or intravenous use, is in an actual shortage that began Oct 13, 2026 and is expected to run until Nov 6, 2026, driven by increased demand.

Sufentanil is used in anaesthesia and pain care — hospitals should confirm supply and alternatives while the shortage runs.

Shortage expected to end: 6 nov. 2026 Toutes les échéances

Poser une question sur ce résumé

Les réponses sont générées par IA à partir de ce résumé et peuvent être inexactes. Vérifiez la source originale avant d'agir.

2 questions gratuites par jour sans compte. Les membres peuvent poser autant de questions qu’ils le souhaitent, gratuitement.

Ceci ne constitue pas un avis médical, juridique ou en matière d'immigration. Les questions sont conservées de manière anonyme pour améliorer nos résumés.

Lire l'original

Source officielle: Sandoz reports supply shortage of sufentanil injection through early November (s'ouvre dans un nouvel onglet) — Health Product Shortages Canada

Signaler un problème

Échéance dans 20 joursSanté publiqueCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Source officielle: Health Product Shortages Canada (s'ouvre dans un nouvel onglet)

Échéance dans 20 joursSanté publiqueCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Source officielle: Health Product Shortages Canada (s'ouvre dans un nouvel onglet)

Échéance dans 39 joursSanté publiqueCanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Source officielle: Health Product Shortages Canada (s'ouvre dans un nouvel onglet)

Échéance dans 18 joursSanté publiqueCanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Source officielle: Health Product Shortages Canada (s'ouvre dans un nouvel onglet)